Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: A meta-analysis of randomized head-to-head trials

International Journal of Cardiology

Volumn 157, Issue 3, 2012, Pages 403-407

  Takagi, Hisato ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Angiotensin II receptor blocker; Meta analysis; Randomized head to head trial; Telmisartan; Triglycerides

Indexed keywords

CANDESARTAN; EPROSARTAN; HIGH DENSITY LIPOPROTEIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; ROSUVASTATIN; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

DRUG RESPONSE; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LETTER; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE;

EID: 84861233544     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.02.008     Document Type: Article

References (35)

1. S.C. Benson, H.A. Pershadsingh, and C.I. Ho Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity Hypertension 43 2004 993 1002
2. T. Wago, T. Yoshimoto, and I. Akaza Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan Hypertens Res 33 2010 796 801
3. T. Inoue, T. Morooka, K. Moroe, H. Ikeda, and K. Node Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR) Horm Metab Res 39 2007 372 376
4. A. Aoki, T. Ogawa, and H. Sumino Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients Heart Vessels 25 2010 195 202
5. R.A. Sanchez, L.D. Masnatta, C. Pesiney, P. Fischer, and A.J. Ramirez Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives J Hypertens 26 2008 2393 2398
6. G. Derosa, A.F. Cicero, and G. Bertone Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study Clin Ther 26 2004 1228 1236
7. Y. Mori, Y. Itoh, and N. Tajima Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes Adv Ther 24 2007 146 153
8. Higgins JP, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
9. D. Follmann, P. Elliott, I. Suh, and J. Cutler Variance imputation for overviews of clinical trials with continuous response J Clin Epidemiol 45 1992 769 773
10. Y. Mori, T. Tanaka, K. Matsuura, J. Yokoyama, and K. Utsunomiya Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE) Adv Ther 28 2011 698 706
11. O. Bahadir, M. Uzunlulu, A. Oguz, and M.A. Bahadir Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome Hypertens Res 30 2007 49 53
12. C. Calvo, R.C. Hermida, D.E. Ayala, and L.M. Ruilope Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension J Hypertens 22 2004 837 846
13. D.A. de Luis, R. Conde, and M. González-Sagrado Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients Nutr Hosp 25 2010 275 279
14. G. Derosa, P.D. Ragonesi, A. Mugellini, L. Ciccarelli, and R. Fogari Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study Hypertens Res 27 2004 457 464
15. G. Derosa, A.F. Cicero, and A. D'Angelo Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha Hypertens Res 29 2006 849 856
16. E.F. Georgescu, R. Ionescu, M. Niculescu, L. Mogoanta, and L. Vancica Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis World J Gastroenterol 15 2009 942 954
17. S.J. Hong, W.J. Shim, and J.I. Choi Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients Am J Cardiol 100 2007 1625 1629
18. S.J. Hong, S.C. Choi, C.M. Ahn, J.H. Park, J.S. Kim, and D.S. Lim Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients Heart 97 2011 1425 1432
19. Z.P. Hu, B.N. Wang, H.Y. Qian, Q. Zhou, W. Wei, and Y. Wang Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients Int Heart J 51 2010 252 258
20. G.Z. Huang, Y.H. Tang, and B.Y. Wang Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity Saudi Med J 32 2011 1017 1021
21. Y. Ichikawa Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome Intern Med 46 2007 1331 1336
22. S.Y. Lim, S.W. Kim, and E.J. Kim Telmisartan versus valsartan in patients with hypertension: effects on cardiovascular, metabolic, and inflammatory parameters Korean Circ J 41 2011 583 589
23. S. Makita, A. Abiko, Y. Naganuma, Y. Moriai, and M. Nakamura Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance Metabolism 57 2008 1473 1478
24. R. Negro, G. Formoso, and H. Hassan The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients J Endocrinol Invest 29 2006 957 961
25. N. Ozaki, Y. Nomura, H. Sobajima, K. Kondo, and Y. Oiso Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus Eur J Intern Med 21 2010 236 239
26. C.V. Rizos, H.J. Milionis, and M.S. Kostapanos Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study Clin Ther 32 2010 492 505
27. A.M. Sharma, J. Davidson, S. Koval, and Y. Lacourcière Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study Cardiovasc Diabetol 6 2007 28
28. H. Hasegawa, H. Takano, and H. Narumi Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients Hypertens Res 34 2011 1179 1184
29. M. Watanabe, K. Inukai, and T. Sumita Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients Intern Med 49 2010 1843 1847
30. S. Yamada, N. Ano, and K. Toda Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro Hypertens Res 31 2008 601 606
31. Y. Yano, S. Hoshide, and J. Ishikawa The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients Am J Hypertens 20 2007 565 572
32. J.A. Dormandy, B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
33. M. Schupp, M. Clemenz, and R. Gineste Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity Diabetes 54 2005 3442 3452
34. A. von Eckardstein, J.R. Nofer, and G. Assmann High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport Arterioscler Thromb Vasc Biol 21 2001 13 27
35. J.J. Repa, S.D. Turley, and J.A. Lobaccaro Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers Science 289 2000 1524 1529